Overview
Alcohol-associated liver disease (ALD) encompasses a spectrum of liver damage ranging from simple steatosis to severe alcoholic hepatitis and cirrhosis, primarily driven by harmful alcohol use. It is a leading cause of advanced liver disease and liver transplantation globally 34.Diagnosis
Clinical History: Detailed history of alcohol consumption patterns 34.
Laboratory Tests: Elevated liver enzymes (AST, ALT), INR, and bilirubin levels 3.
Imaging: Ultrasound or CT scan to assess liver morphology and detect fibrosis or cirrhosis 3.
Histological Assessment: Liver biopsy for definitive diagnosis and staging of fibrosis 3.
Severity Grading: Model for End-Stage Liver Disease (MELD) score, particularly useful for alcoholic hepatitis severity (>20 indicates severe disease) 3.Management
Abstinence: Essential for long-term outcomes; pharmacotherapy and behavioral interventions support cessation 34.
Severe Alcoholic Hepatitis: Corticosteroids (e.g., prednisolone 40 mg daily for 28-42 days) improve 1-month survival 3.
Supportive Care: Nutritional support, management of complications (ascites, encephalopathy), and treatment of infections 3.
Multidisciplinary Approach: Integration of hepatology and addiction care enhances outcomes and reduces readmissions 1.
Pharmacotherapy for AUD: Limited specific drug recommendations in abstracts; consider naltrexone, acamprosate, or disulfiram based on clinical guidelines 2.Special Populations
Pregnancy: Specific management strategies not detailed in abstracts; multidisciplinary care crucial 2.
Elderly: Increased complexity due to comorbidities; tailored abstinence and supportive care essential 3.
Comorbidities: Management requires addressing both alcohol use disorder and coexisting conditions 3.Key Recommendations
Integrate hepatology and addiction care for hospitalized patients with alcohol use disorder to reduce future liver-related decompensating events (Evidence: Strong 1).
Use corticosteroids for patients with severe alcoholic hepatitis to improve short-term survival (Evidence: Strong 3).
Promote abstinence through multidisciplinary support and consider pharmacotherapy for alcohol use disorder (Evidence: Moderate 23).References
1 George P, Marshall C, Zhang W, Goodman R, Butler M, Patel SJ et al.. Integrating hepatology with addiction care for inpatients with alcohol use disorder reduces future liver-related events. Hepatology communications 2025. link
2 Ilagan-Ying YC. An AUDacious Proposal: How to Improve Gastroenterology Fellow Training for Alcohol Use Disorder and Alcohol-Associated Liver Disease. Digestive diseases and sciences 2025. link
3 Jophlin LL, Singal AK, Bataller R, Wong RJ, Sauer BG, Terrault NA et al.. ACG Clinical Guideline: Alcohol-Associated Liver Disease. The American journal of gastroenterology 2024. link
4 Addolorato G, Abenavoli L, Dallio M, Federico A, Germani G, Gitto S et al.. Alcohol associated liver disease 2020: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2020. link